3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: A Benchmark H+,K+-ATPase Inhibitor for Gastric Acid Secretion Research

Executive Summary: 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845, APExBIO) is a potent inhibitor of H+,K+-ATPase, with an in vitro IC₅₀ of 5.8 μM and a histamine-induced acid formation IC₅₀ of 0.16 μM, offering validated antiulcer and antisecretory activity (APExBIO, 2024). The compound is supplied as a solid at >98% purity, confirmed by HPLC and NMR, and demonstrates optimal solubility (≥17.27 mg/mL) in DMSO (APExBIO, 2024). It is optimal for research targeting the proton pump (H+,K+-ATPase) signaling pathway in gastric acid-related disorders. Recent literature establishes the relevance of acid secretion modulation in experimental models of peptic ulcer disease and highlights the importance of high-purity inhibitors for reproducibility in pharmacological workflows (Kong et al., 2025).

Biological Rationale

Gastric acid secretion is regulated by the parietal cell H+,K+-ATPase pump, a key target for antiulcer drug development (see profile). Dysregulated acid secretion underlies a range of gastrointestinal disorders, including peptic ulcer disease and gastroesophageal reflux disease (GERD). Selective inhibition of the H+,K+-ATPase enzyme blocks the terminal step in acid production, providing a mechanistic basis for antisecretory and antiulcer effects. The robust modulation of this target is fundamental for disease modeling and drug screening studies in gastroenterology research.

Mechanism of Action of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

This compound acts as a competitive and selective inhibitor of the gastric H+,K+-ATPase proton pump. The IC₅₀ for direct enzymatic inhibition is 5.8 μM, determined under standardized in vitro conditions (pH 7.4, 37°C, 30 min incubation; APExBIO). For histamine-induced acid formation in gastric mucosal cells, the IC₅₀ is 0.16 μM, demonstrating high potency in functional systems. The agent binds to the enzyme’s catalytic domain, blocking ATPase-mediated proton exchange across the parietal cell membrane. This interruption leads to rapid and profound inhibition of acid secretion, as validated in cell and tissue-based assays. Action is reversible on washout, and the compound does not covalently modify the target enzyme, distinguishing it from irreversible proton pump inhibitors.

Evidence & Benchmarks

• H+,K+-ATPase inhibition IC₅₀: 5.8 μM in cell-free enzymatic assay at 37°C, pH 7.4 (APExBIO, 2024).
• Histamine-induced acid secretion IC₅₀: 0.16 μM in isolated gastric gland assays (APExBIO, 2024).
• Purity: ≥98% (HPLC and NMR-validated), supporting reproducible pharmacological results (APExBIO, 2024).
• Solubility: ≥17.27 mg/mL in DMSO; insoluble in water and ethanol (APExBIO, 2024).
• Utility for antiulcer activity: Demonstrated in gastric acid secretion models; enables studies of peptic ulcer disease mechanisms (see here for research expansion).
• Supports reproducible cell-based and cytotoxicity assays due to high selectivity and validated handling protocols (see protocol detail).
• Stable storage at -20°C as a solid; not recommended for long-term solution storage to maintain integrity (APExBIO, 2024).
• Not for diagnostic or medical use; exclusively for laboratory research (APExBIO, 2024).
• Recent literature underscores the link between gastric acid secretion modulation and gut-brain axis research, with potential intersections in neuroinflammatory models (Kong et al., 2025).

Applications, Limits & Misconceptions

The robust inhibition profile of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide makes it well-suited for:

• Gastric acid secretion research (e.g., mechanistic studies, screening of antiulcer agents).
• Functional studies of the H+,K+-ATPase signaling pathway.
• Peptic ulcer disease and GERD animal model development.
• Investigations into the gut-brain axis, especially where acid secretion impacts neuroinflammatory responses (see here). This article extends previous summaries by integrating recent neuroinflammation-gastroenterology findings.
• Benchmarking against other proton pump inhibitors ('ic omeprazole') for efficacy and selectivity.

Common Pitfalls or Misconceptions

• Not suitable for in vivo therapeutic use: This compound is intended exclusively for research, not for patient administration (APExBIO).
• Solubility limitations: Insoluble in water and ethanol; improper solvent selection may hinder assay performance.
• Storage instability: Long-term storage in solution can lead to degradation; always prefer solid-state storage at -20°C.
• Not a covalent/irreversible inhibitor: Does not irreversibly bind H+,K+-ATPase; effects are reversible and may differ from classic proton pump inhibitors.
• Not validated for non-gastric ATPase targets: Activity outside the gastric acid secretion pathway is uncharacterized.

Workflow Integration & Parameters

For optimal use in laboratory settings, the following parameters are recommended:

• Prepare solutions in DMSO at concentrations up to 17.27 mg/mL.
• Store solid at -20°C; avoid repeated freeze-thaw cycles.
• Use in cell-free or cell-based assays targeting H+,K+-ATPase, maintaining pH and temperature consistency (typically pH 7.4, 37°C).
• For cytotoxicity or viability assays, follow established protocols to minimize solvent effects (see troubleshooting guide). This guidance clarifies the impact of solvent choice and purity on reproducibility, expanding previous discussions.
• Reference validated controls (e.g., 'ic omeprazole') for benchmarking.

The A2845 kit is supplied by APExBIO with technical documentation for reproducible assay development.

Conclusion & Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845) is a benchmark H+,K+-ATPase inhibitor for research in gastric acid secretion and antiulcer activity. Its high selectivity, validated purity, and robust handling characteristics make it a preferred tool for disease modeling and pathway analysis. Emerging evidence suggests further potential in gut-brain axis and neuroinflammation studies, expanding its utility beyond traditional gastroenterology (Kong et al., 2025). For comprehensive molecular and experimental details, researchers should consult both the APExBIO product page and recent application-focused articles (see broader context—this article updates with new intersectional insights).